Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nafamostat - Chong Kun Dang

X
Drug Profile

Nafamostat - Chong Kun Dang

Alternative Names: CKD-314; Nafabelltan; Nafamostat mesilate - Chong Kun Dang

Latest Information Update: 13 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institut Pasteur Korea
  • Developer Chong Kun Dang
  • Class Anti-inflammatories; Anticoagulants; Antivirals; Guanidines; Mucolytics; Small molecules
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID-19 pneumonia

Most Recent Events

  • 30 Jun 2021 Phase-III clinical trials in COVID-19 pneumonia (Adjunctive treatment) in South Korea (IV) (NCT04871646)
  • 05 May 2021 Chong Kun Dang Pharmaceutical plans a phase III trial for COVID-19 pneumonia in June 2021 (NCT04871646)
  • 31 Jan 2021 Chong Kun Dang Pharmaceutical completes a phase II trial in COVID-2019 pneumonia (Adjunctive treatment) in Russia (NCT04623021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top